Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 8, 1997

View Archived Issues

Neose's NE-1530 enters phase I for otitis media

SangStat signs ciclosporin agreement with Amgen

Egis reports safe and effective new anxiolytic

Alcon compounds with dual antioxidant/cysteine prodrug properties

Structurally distinct class of 5-HT1B antagonists prepared at SmithKline Beecham

Analgesics under evaluation at Ortho

Egis prepares new AMPA receptor antagonists

Byk Gulden presents new PDE IV inhibitors

IL-12 for treatment of malignant tumors

Zeneca selects EGFR-TK inhibitor for clinical evaluation

IntraBiotics signs manufacturing and supply agreement for IB-367

HMR begins phase II trial with GA-EPO

Antiinflammatory and COX-2-inhibitory effects reported for rutaecarpine

Epstein-Barr virus vaccine enters phase I

Beneficial effects of PLA2 inhibitor in animal models of acute pancreatitis and ARDS

NeoTherapeutics: Q3 1997 highlights

Novel therapeutic for anxiety and depression enters phase I

Pharmacopeia and Bristol-Myers Squibb collaborate on chemokine receptors

SunPharm's anticancer drug completes phase I

MedImmune announces collaborations for MEDI-493

InSite Vision brings its once-daily glaucoma treatment to clinical trials

Another ANDA approval for Gensia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...